Physician profile
Brian D Hale
NPI 1457355059
$5,187.14
in general payments reported to CMS, 2019-2025
43 companies · $744 in 2025
The $744 reported for 2025 was more than what a typical Urology provider received nationally (typical 2025 total: $631).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $825 · 2020: $709 · 2021: $481 · 2022: $536 · 2023: $1,212 · 2024: $682 · 2025: $744.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,623 · Education: $14.11.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,623.38 |
| Education | $14.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dendreon Pharmaceuticals LLC | $479.47 | 2019-2025 | Provenge |
| Abbvie INC. | $372.76 | 2019-2025 | |
| Sumitomo Pharma America, INC. | $305.73 | 2023-2025 | Orgovyx, Gemtesa |
| Myriad Genetic Laboratories, INC. | $251.03 | 2020-2024 | Prolaris |
| Procept Biorobotics Corporation | $231.35 | 2021-2025 | Aquabeam System |
| Astellas Pharma US INC | $227.64 | 2019-2023 | Xtandi, Myrbetriq |
| Pfizer INC. | $218.05 | 2019-2025 | |
| Axonics, INC. | $210.18 | 2023-2024 | Axonics, Bulkamid |
| Astrazeneca Pharmaceuticals LP | $202.99 | 2020-2023 | Lynparza |
| Boston Scientific Corporation | $195.94 | 2019-2025 | Rezum Generator, Spaceoar Vue System - 10ml |
| Blue Earth Diagnostics | $187.56 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $185.84 | 2019-2024 | |
| Ferring Pharmaceuticals INC. | $164.52 | 2019-2025 | Adstiladrin |
| Neotract INC. | $147.22 | 2019-2020 | |
| Amgen INC. | $127.25 | 2019-2021 |
Show all 41 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $127.21 | 2019-2025 | Erleada |
| Accord Healthcare, INC. | $124.51 | 2023-2025 | |
| Teleflex LLC | $116.27 | 2021-2024 | Urolift |
| Urogen Pharma, INC. | $115.71 | 2021-2025 | Jelmyto |
| Telix Pharmaceuticals | $105.45 | 2023-2024 | Illuccix |
| Novartis Pharmaceuticals Corporation | $105.05 | 2023-2025 | |
| Acerus Pharmaceuticals Corporation | $91.12 | 2020-2021 | |
| Coloplast Corp | $88.66 | 2019-2021 | |
| Allergan, INC. | $87.25 | 2019-2021 | |
| Endo Pharmaceuticals INC. | $83.33 | 2020 | |
| Antares Pharma, INC. | $82.19 | 2019-2025 | Xyosted |
| Olympus America INC. | $78.32 | 2024-2025 | Itind System |
| Myovant Sciences INC. | $61.84 | 2021-2022 | |
| Tolmar, INC. | $56.33 | 2023-2025 | Eligard |
| Merck Sharp & Dohme LLC | $50.99 | 2023-2024 | Lynparza, Keytruda |
| Laborie Medical Technologies Corp. | $48.48 | 2023-2025 | |
| Tempus Ai, INC | $48.09 | 2024-2025 | Xt Cdx |
| Urovant Sciences INC | $46.03 | 2022 | |
| Azurity Pharmaceuticals, INC. | $42.27 | 2025 | Azmiro |
| Clarus Therapeutics INC. | $27.62 | 2021 | |
| Bioprotect Medical, INC. | $19.24 | 2024 | Bioprotect Balloon Implant System |
| Angiodynamics, INC. | $17.12 | 2022 | |
| Verity Pharmaceuticals INC. | $15.39 | 2025 | Tlando |
| Tolmar Pharmaceuticals, INC. | $14.43 | 2020 | |
| Zyla Life Sciences, INC. | $14.40 | 2019 | |
| Abbott Laboratories | $12.31 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$66,817.72 in ownership or investment interests, as reported to CMS. These are holdings a clinician or an immediate family member has in a company, not payments received.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Brian Hale listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.